Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
Craig-Hallum Keeps Their Buy Rating on LifeMD (LFMD)
B.Riley Financial Maintains LifeMD(LFMD.US) With Buy Rating, Cuts Target Price to $11
LifeMD Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on LifeMD, Maintains $15 Price Target
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA) and LifeMD (LFMD)
LifeMD Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on LifeMD, Maintains $15 Price Target
B. Riley Trims Price Target on LifeMD to $11 From $12, Maintains Buy Rating
Strong Growth and Positive Outlook Justify Buy Rating for LifeMD
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
LifeMD (LFMD) Gets a Buy From Craig-Hallum
KeyBanc Adjusts Price Target on LifeMD to $10 From $12, Maintains Overweight Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Unicycive Therapeutics (UNCY), LifeMD (LFMD) and Teladoc (TDOC)
LifeMD Analyst Ratings
LifeMD Analyst Ratings
LifeMD (LFMD) Gets a Buy From Craig-Hallum
B. Riley Securities: Reiterated LifeMD (LFMD.US) rating and adjusted from buy to buy rating, target price of $12.00.
LifeMD Analyst Ratings